---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-052036"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:34:22.606054+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Apimeds Pharmaceuticals appoints Sungjoon Chae as Co-CEO

## Summary
- Sungjoon Chae appointed Co-CEO effective May 4, 2026, pursuant to a stockholder nomination.
- No family relationships or related party transactions with company officers or directors.
- Compensation terms for Chae have not yet been determined; will be disclosed when finalized.
- Chae holds a Master of Architecture in Urban Design from Harvard University and specializes in large-scale real estate and urban regeneration.
- Existing CEO Dr. Vin Menon continues as CEO; Chae serves as Co-CEO.

## SEC filing metadata
- accession: 0001213900-26-052036
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390026052036/0001213900-26-052036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390026052036/ea0289213-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-052036
- JSON: https://secwatch.observer/filing/0001213900-26-052036.json
- Plain text: https://secwatch.observer/filing/0001213900-26-052036.txt

## Key facts
- Executive change
  Sungjoon Chae was appointed as Co-Chief Executive Officer at Apimeds Pharmaceuticals US, Inc..
  - Action: appointed
  - Role: Co-Chief Executive Officer
  source text: On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company "), the board of directors of the Company (the " Board ") appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894525/000121390026052036/0001213900-26-052036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.